Clinical Trial Update: A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing rifaximin versus lactulose in hospitalized cirrhotic patients with renal failure has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy

Drugs mentioned

• LACTULOSE (Lactulose)
• XIFAXAN (rifaximin)

Snippet

Sponsor: NYU Langone Health | Conditions: Hepatic Encephalopathy | Phase 3 | Status: WITHDRAWN